1-20 of 52
Eric K. Rowinsky
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

Monica Mita, Kevin R. Kelly, Alain Mita, Alejandro D. Ricart, Ofelia Romero, Anthony Tolcher, Laurel Hook, Chukwuemeka Okereke, Ilya Krivelevich, Daniel P. Rossignol, Francis J. Giles, Eric K. Rowinsky, Chris Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (1): 193–200.
https://doi.org/10.1158/1078-0432.CCR-10-0010
Published: 04 January 2011
View article titled, Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies
Open the PDF for Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies in another window
Journal Articles

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

Thomas Winder, Wu Zhang, Dongyun Yang, Yan Ning, Pierre Bohanes, Armin Gerger, Peter M. Wilson, Alexandra Pohl, David J. Mauro, Christiane Langer, Eric K. Rowinsky, Heinz-Josef Lenz
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (22): 5591–5602.
https://doi.org/10.1158/1078-0432.CCR-10-2092
Published: 14 November 2010
View article titled, Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type <em>KRAS</em> mCRC Patients
Open the PDF for Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type <em>KRAS</em> mCRC Patients in another window
Journal Articles

Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors

Quincy Chu, Alain Mita, Bahram Forouzesh, Anthony W. Tolcher, Gary Schwartz, Antonio Nieto, Arturo Soto-Matos, Vicente Alfaro, Claudia Lebedinsky, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (9): 2656–2665.
https://doi.org/10.1158/1078-0432.CCR-10-0062
Published: 28 April 2010
View article titled, Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

Bart Kuenen, Petronella O. Witteveen, Rita Ruijter, Giuseppe Giaccone, Aruna Dontabhaktuni, Floyd Fox, Terry Katz, Hagop Youssoufian, Junming Zhu, Eric K. Rowinsky, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1915–1923.
https://doi.org/10.1158/1078-0432.CCR-09-2425
Published: 14 March 2010
View article titled, A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG<sub>1</sub> Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG<sub>1</sub> Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies in another window
Journal Articles

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Zhaojing Zhong, Kyla Driscoll Carroll, Desiree Policarpio, Carla Osborn, Michael Gregory, Rajiv Bassi, Xenia Jimenez, Marie Prewett, Gregory Liebisch, Kris Persaud, Douglas Burtrum, Su Wang, David Surguladze, Stanley Ng, Heather Griffith, Paul Balderes, Jacqueline Doody, Jonathan D. Schwartz, Hagop Youssoufian, Eric K. Rowinsky, Dale L. Ludwig, Larry Witte, Zhenping Zhu, Yan Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (4): 1191–1205.
https://doi.org/10.1158/1078-0432.CCR-09-1634
Published: 15 February 2010
View article titled, Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells
Open the PDF for Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Sanjay Goel, Alain C. Mita, Monica Mita, Eric K. Rowinsky, Quincy S. Chu, Nancy Wong, Christopher Desjardins, Fang Fang, Mendel Jansen, Dale E. Shuster, Sridhar Mani, Chris H. Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4207–4212.
https://doi.org/10.1158/1078-0432.CCR-08-2429
Published: 15 June 2009
View article titled, A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

Bahram Forouzesh, Manuel Hidalgo, Quincy Chu, Alain Mita, Monica Mita, Garry Schwartz, José Jimeno, Javier Gómez, Vicente Alfaro, Claudia Lebedinsky, Patrik Zintl, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3591–3599.
https://doi.org/10.1158/1078-0432.CCR-08-2889
Published: 18 May 2009
View article titled, Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies
Open the PDF for Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies in another window
Journal Articles

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Alain C. Mita, Louis J. Denis, Eric K. Rowinsky, Johann S. DeBono, Andrew D. Goetz, Leonel Ochoa, Bahram Forouzesh, Muralidhar Beeram, Amita Patnaik, Kathleen Molpus, Dorothée Semiond, Michèle Besenval, Anthony W. Tolcher
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (2): 723–730.
https://doi.org/10.1158/1078-0432.CCR-08-0596
Published: 15 January 2009
View article titled, Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors

Alejandro D. Ricart, Jordan D. Berlin, Kyriakos P. Papadopoulos, Samira Syed, Daniel W. Drolet, Charlotte Quaratino-Baker, Julie Horan, Jon Chick, Wendy Vermeulen, Anthony W. Tolcher, Eric K. Rowinsky, Mace L. Rothenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7947–7955.
https://doi.org/10.1158/1078-0432.CCR-08-0864
Published: 01 December 2008
View article titled, Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors
Open the PDF for Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors in another window
Journal Articles

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

Georg Lurje, Fumio Nagashima, Wu Zhang, Dongyun Yang, Heung M. Chang, Michael A. Gordon, Anthony El-Khoueiry, Hatim Husain, Peter M. Wilson, Robert D. Ladner, David J. Mauro, Christiane Langer, Eric K. Rowinsky, Heinz-Josef Lenz
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7884–7895.
https://doi.org/10.1158/1078-0432.CCR-07-5165
Published: 01 December 2008
View article titled, Polymorphisms in <em>Cyclooxygenase-2</em> and <em>Epidermal Growth Factor Receptor</em> Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab
Open the PDF for Polymorphisms in <em>Cyclooxygenase-2</em> and <em>Epidermal Growth Factor Receptor</em> Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab in another window
Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

Johann S. de Bono, Rebecca Kristeleit, Anthony Tolcher, Peter Fong, Simon Pacey, Vasilios Karavasilis, Monica Mita, Heather Shaw, Paul Workman, Stan Kaye, Eric K. Rowinsky, Wynne Aherne, Peter Atadja, Jeffrey W. Scott, Amita Patnaik
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6663–6673.
https://doi.org/10.1158/1078-0432.CCR-08-0376
Published: 16 October 2008
View article titled, Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

Quincy S.C. Chu, Mary E. Cianfrocca, Lori J. Goldstein, Meg Gale, Nicholas Murray, Jill Loftiss, Nikita Arya, Kevin M. Koch, Lini Pandite, Ronald A. Fleming, Elaine Paul, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4484–4490.
https://doi.org/10.1158/1078-0432.CCR-07-4417
Published: 15 July 2008
View article titled, A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer
Open the PDF for A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer in another window
Journal Articles

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

Eric K. Rowinsky, Hagop Youssoufian, James R. Tonra, Phillip Solomon, Douglas Burtrum, Dale L. Ludwig
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5549s–5555s.
https://doi.org/10.1158/1078-0432.CCR-07-1109
Published: 17 September 2007
View article titled, IMC-A12, a Human IgG<sub>1</sub> Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor
Open the PDF for IMC-A12, a Human IgG<sub>1</sub> Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor in another window
Journal Articles

Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy

Hagop Youssoufian, Daniel J. Hicklin, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5544s–5548s.
https://doi.org/10.1158/1078-0432.CCR-07-1107
Published: 17 September 2007
View article titled, Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy
Open the PDF for Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy in another window
Journal Articles

Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel

Alain C. Mita, Anthony J. Olszanski, Richard C. Walovitch, Raymond P. Perez, Kathleen MacKay, David P. Tuck, Cecilia Simmons, Susan Hammond, Monica M. Mita, Muralidhar Beeram, Anne J. Stone, Eric K. Rowinsky, Lionel D. Lewis
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3293–3301.
https://doi.org/10.1158/1078-0432.CCR-06-2496
Published: 01 June 2007
View article titled, Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel
Open the PDF for Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel in another window
Journal Articles

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Chris H. Takimoto, Lisa A. Hammond-Thelin, Jane E. Latz, Leonardo Forero, Muralidhar Beeram, Bahram Forouzesh, Johann de Bono, Anthony W. Tolcher, Amita Patnaik, Pamela Monroe, Leslie Wood, Karen B. Schneck, Romnee Clark, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (9): 2675–2683.
https://doi.org/10.1158/1078-0432.CCR-06-2393
Published: 01 May 2007
View article titled, Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer
Open the PDF for Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies

Eric K. Rowinsky, Muralidhar Beeram, Lisa A. Hammond, Garry Schwartz, Johann De Bono, Baharam Forouzesh, Quincy Chu, Jane E. Latz, Shengyan Hong, William John, Binh Nguyen
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 532–539.
https://doi.org/10.1158/1078-0432.CCR-06-1606
Published: 25 January 2007
View article titled, A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies in another window
Journal Articles

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

Amita Patnaik, Debra Wood, Anthony W. Tolcher, Marta Hamilton, Jeffrey I. Kreisberg, Lisa A. Hammond, Garry Schwartz, Muralidhar Beeram, Manuel Hidalgo, Monica M. Mita, Julie Wolf, Paul Nadler, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (24): 7406–7413.
https://doi.org/10.1158/1078-0432.CCR-06-1886
Published: 22 December 2006
View article titled, Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
Open the PDF for Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

Manuel Hidalgo, Jan C. Buckner, Charles Erlichman, Marilyn S. Pollack, Joseph P. Boni, Gary Dukart, Bonnie Marshall, Lisa Speicher, Laurence Moore, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5755–5763.
https://doi.org/10.1158/1078-0432.CCR-06-0118
Published: 04 October 2006
View article titled, A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
Open the PDF for A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer in another window
Journal Articles

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

Alain C. Mita, Lisa A. Hammond, Peter L. Bonate, Geoffrey Weiss, Heather McCreery, Samira Syed, Mitchell Garrison, Quincy S.C. Chu, Johann S. DeBono, Christopher B. Jones, Steve Weitman, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5207–5215.
https://doi.org/10.1158/1078-0432.CCR-06-0179
Published: 01 September 2006
View article titled, Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors in another window